GSK and CureVac have restructured an ongoing partnership that gives the British pharma giant control over the development of experimental mRNA-based Covid and flu vaccines, the companies said Wednesday.
CureVac, the German biotech that focuses on mRNA vaccines, will receive an initial payment of €400 million upfront ($430 million) from GSK, and is eligible for another €1.05 billion ($1.1 billion) in future payments if certain milestones are hit. In exchange, GSK is taking full control over the development, manufacturing, and marketing of vaccines for seasonal flu and Covid that are currently in Phase 2 trials, and a bird flu vaccine in Phase 1 studies.
Click this link for the original source of this article.
Author: Adam Feuerstein
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.